Basiliximab interferes with the detection of soluble IL-2 receptor by the Immulite Immunoassay system.
The use of the Immulite Automated Immunoassay system is becoming an increasingly popular method for accurate and fast measurement of sIL-2R in serum. Here, we report that detection of sIL-2R using the Immulite Immunoassay system in serum samples of patients who are treated with basiliximab, a monoclonal antibody against the alpha-chain of the IL-2 receptor, may lead to false measurements.
Warlé
Michiel C
MC
Department of Surgery, Erasmus Medical Center Rotterdam, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
Kwekkeboom
Jaap
J
Tilanus
Hugo W
HW
Metselaar
Herold J
HJ
D000911:Antibodies, Monoclonal / Q000097:blood* / Q000627:therapeutic use; D000077552:Basiliximab; D001667:Binding, Competitive; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D007166:Immunosuppressive Agents / Q000097:blood / Q000627:therapeutic use; D016031:Liver Transplantation / Q000276:immunology; D015375:Receptors, Interleukin-2 / Q000097:blood*; D011993:Recombinant Fusion Proteins; D012995:Solubility; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab